Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

Biotechnology

Healthcare
$9.07 -1.39%

-$0.26 today

Market cap
$775.03M
Beta
1.60
P/E (TTM)
-9.1
EPS (TTM)
-$1.98
52W Low $4.12High $25.77

Volume 1.26M

Average 1.02M

GLUE Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Monte Rosa Therapeutics, Inc.NASDAQ: GLUE

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 103.6% from a year ago

Cash & equivalents stood at $159.86M at the end of Q1 FY2026, up 103.6% from a year earlier and up 23.1% from the prior quarter. Over 3 fiscal years it compounded at +33.2% a year.

Context

  • Cash & equivalents amounted to 21.7% of total assets at the end of Q1 FY2026, up 1.7 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +103.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$159.86M+23.1% QoQ
Last fiscal yearDec 2025
$129.88M-42.1% YoY
Year agoMar 2025
$78.53M+103.6% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+103.6%——
1 year-42.1%——
3-year CAGR+33.2%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
129.88M USD
Year-over-year change
-42.1%
4-year CAGR
-21.7%

Cash & Equivalents vs competitors

How GLUE compares with its peers on the latest reported figures

  • GLUE's Mar 2026 cash & equivalents of $159.86M is the 2nd highest of the 4 companies compared; the peer median is $87.3M.
  • Its year-over-year change of +103.6% is the 2nd highest of 4, against a peer median of +19.5%.
  • Cash & equivalents amounts to 21.7% of total assets for GLUE, versus a peer median of 18.6%.
GLUE Competitors Peer median
Cash & Equivalents for GLUE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NRIXNurix Therapeutics, Inc.Aug 2026$720.24M +818.2%+56.5%60.3%
GLUEMonte Rosa Therapeutics, Inc.Mar 2026$159.86M +103.6%+33.2%21.7%
ARVNArvinas, Inc.Mar 2026$87.3M +7.8%+20.7%13.5%
CCCCC4 Therapeutics, Inc.Mar 2026$61.27M +19.5%+35.9%18.6%
Peer median (excluding GLUE) $87.3M+19.5%+35.9%18.6%

Competitors are the stored peer set for GLUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents346.07M54.91M128.1M224.25M129.88M
Short-term Investments0207.91M104.31M147.9M247.22M
Net Receivables07.66M505K173K4.6M
Inventory00000
Other Current Assets05.4M3.29M5.12M11.48M
Total Current Assets348.67M275.89M236.21M377.44M393.19M
Property, Plant & Equipment (Net)12.33M61.91M62.61M56.31M50.37M
Goodwill00000
Intangible Assets00000
Long-term Investments5.34M0000
Tax Assets00000
Other Non-current Assets04.6M4.93M4.98M5.1M
Total Non-current Assets17.66M66.5M67.54M61.29M55.47M
Total Assets366.33M342.39M303.76M438.73M448.66M
Account Payables6.56M7.86M11.15M17.22M3.55M
Short-term Debt00000
Tax Payables00000
Deferred Revenue0017.68M117.23M29.57M
Other Current Liabilities840K10.64M9.26M11.57M11.58M
Total Current Liabilities16.64M25.57M46.59M156.95M64.21M
Long-term Debt000034.79M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)0032.32M16.15M111.33M
Other Non-current Liabilities2.18M1.53M2.71M3.7M5.27M
Total Non-current Liabilities2.18M45.41M77.91M58.85M151.39M
Total Liabilities18.81M70.98M124.51M215.8M215.6M
Common Stock5K5K5K6K7K
Retained Earnings(122.04M)(230.54M)(365.89M)(438.59M)(477.21M)
Accumulated OCI(2.02M)(1.75M)(2.72M)(3.36M)(3.83M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity347.52M271.41M179.25M222.94M233.06M
Total Debt047M46.04M42.72M39.19M
Net Debt(346.07M)(7.91M)(82.06M)(181.54M)(90.69M)

Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

Intrinsic Alpha fair value

Locked

Current Price

$9.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.